A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...
May 3, 2024
0
52
Despite significant progress in treating gastrointestinal (GI) cancers through surgical resection, chemotherapy, radiotherapy, and targeted therapy, the objective response rate (ORR) for immune checkpoint inhibitor (ICI) ...
Apr 30, 2024
0
0
Researchers from the Organoid group have developed a new organoid model that can be used to study the thymus. The organoids are derived from mouse thymus tissue, specifically model thymic epithelial cells (TECs). These cells ...
Apr 29, 2024
0
33
Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system. In this way, the body presumably curbs destructive immune reactions.
18 hours ago
0
27
The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma—a serious and often fatal brain cancer—suppresses the immune system so that the tumor can grow ...
19 hours ago
0
50
As COVID-19 becomes endemic, an important group of people who continue to require vaccination is future birth cohorts of children. Yet, in the face of everchanging variants, as well as the waning of antibodies with time after ...
Apr 30, 2024
0
7
University at Buffalo researchers have found that the active form of a gene promotes a broad range of protective traits. The gene is found in 75% of the population and is known to protect against neurodegeneration. Now, UB ...
Apr 30, 2024
0
39
Cancer immunotherapy, which leverages the body's immune system to target tumors, has emerged as a pivotal strategy in oncology. This paradigm shift from conventional treatments offers a more precise method to neutralize cancer ...
Apr 30, 2024
0
1
An extensive analytical study conducted at the Terasaki Institute for Biomedical Innovation (TIBI) has revealed an association between favorable survival outcomes for melanoma patients and the presence of higher populations ...
May 2, 2024
0
1
A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented ...
Apr 29, 2024
0
0
